Section Arrow
QURE.NASDAQ
- uniQure NV
Quotes are at least 15-min delayed:2026/08/05 12:16 EDT
Regular Hours
Last
 43.785
+0.105 (+0.24%)
Day High 
44.5099 
Prev. Close
43.68 
1-M High
44.99 
Volume 
193.46K 
Bid
43.7
Ask
43.81
Day Low
43.22 
Open
43.9 
1-M Low
35.34 
Market Cap 
3.03B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 40.73 
20-SMA 41.05 
50-SMA 37.48 
52-W High 71.5 
52-W Low 8.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.06/-2.23
Enterprise Value
3.09B
Balance Sheet
Book Value Per Share
4.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
16.10M
Operating Revenue Per Share
1.61
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GERNGeron Corp1.59+0.25+18.66%-- 
PGENPrecigen7.035+0.505+7.73%-- 
RXRXRecursion Pharmaceuticals3.1701-0.1399-4.23%-- 
IOVAIovance Biotherapeutics4.4599+0.0999+2.29%-- 
IBRXImmunityBio7.37+0.42+6.04%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.